ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial OfficerGlobeNewsWire · Oct 6, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in SeptemberGlobeNewsWire · Sep 1, 2026
Promis Neurosciences Q2 Earnings Call HighlightsMarketBeat · Aug 13, 2026
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsGlobeNewsWire · Aug 13, 2026
Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product MomentumGuruFocus · Aug 4, 2026
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026GlobeNewsWire · Aug 3, 2026ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$1.38 | -$1.28 | Beat |
| May 11, 2026 | -$1.06 | -$1.26 | Miss |
| Mar 30, 2026 | -$4.22 | -$4.11 | Beat |
| Nov 12, 2025 | -$3.75 | -$6.00 | Miss |
| Aug 13, 2025 | -$5.50 | -$7.25 | Miss |
| May 12, 2025 | -$3.00 | -$5.25 | Miss |